Biogen shares surge on plan to resurrect Alzheimer’s drug
Analysts warn that the FDA is under no obligation to approve the drug
22 October 2019 - 23:00
Bengaluru — Biogen revived plans on Tuesday to seek US approval for Alzheimer’s treatment Aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients suffering from the disease.
The drugmaker’s shares soared 27% in response to the decision, recouping almost all of the $18bn lost from the company’s market value when it said in March it was abandoning the two studies...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.